There are described RORγ modulators of the formula (I), ##STR00001##
and formula (II) ##STR00002##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

There are described RORγ modulators of the formula (I), ##STR00001##
and formula (II) ##STR00002##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

A phenol derivative of the present invention has a structure as represented by the formula (I):

##STR00001##

The functional groups are defined in the description. The phenol derivative can be used as the antioxidant in lubricating oil, lubricating grease, plastic, rubber, or can be used as the base oil of the lubricating oil and the lubricating grease and the antiwear additive of the lubricating oil and the lubricating grease.

p-phenylenediamine derivatives as potassium channel regulators and preparation methods and medical applications thereof. A compound represented by general formula A or a pharmaceutically acceptable salt thereof. A preparation method of the compound and a use of the same as a potassium channel opener.

Compounds of the formula I

##STR00001##

are provided. These compounds can inhibit c-Kit kinase and can be employed for the treatment of cancer.

Compounds of the formula I

##STR00001##

are provided. These compounds can inhibit c-Kit kinase and can be employed for the treatment of cancer.

The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.

The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.

The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.

Disclosed are antimicrobial articles and surfaces, as well as methods of making such articles and surfaces.